/DISREGARD RELEASE: Ractigen Therapeutics/

We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued 7:30AM12-Dec-2025 over PR Newswire, as the release contained erroneous information.

SOURCE Ractigen Therapeutics